Navigation Links
RegenoCELL Gives Second Half Update
Date:7/12/2011

NATICK, Mass., July 12, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) – gave a second half update.  James F. Mongiardo, Chief Executive Officer, reported that plans are being made for the conduct of clinical trials in the United States and Europe for its stem cell therapy. Simultaneous with these efforts, the company's foreign subsidiary, Regenocell, Ltd., reported that it expects to begin marketing the company's stem cell product for the treatment of congestive heart failure and peripheral artery disease.  Sales have been previously made through distributors.

In the second half, Regenocell, Ltd. expects to increase revenues through direct sales, additional distributors and offering the autologous stem cell treatment in more countries.

About RegenoCELL Therapeutics, Inc.

RegenoCELL Therapeutics, Inc. is a stem cell therapy company using adult stem cells for autologous treatment of patients.  The Company plans to obtain regulatory approval in the United States and the European Community to market its stem cell treatments.  Through its wholly owned foreign subsidiaries, the company is marketing its stem cell treatments for transplantation in jurisdictions where autologous therapy is permitted.

Cardiac Disease

There are therapies to treat congestive heart failure.  But there comes a treatment point when the only option may be a heart transplant.  Over 25,000 people are on the transplant lists but fewer than 2,500 receive one. The mean life expectancy of a heart transplant recipient is 8 years. A new therapeutic approach to treat this disease is needed.

Peripheral Artery Disease

The same RCLL adult stem cell treatment can be used to treat peripheral artery disease. In the United States, there are over 10 million people suffering from the lack of sufficient blood flow to the extremities with an equal number in Europe. This disease is most often experienced by diabetics in their toes and lower legs.

Since 2005, the company's stem cell therapy has successfully treated over 500 patients.  The typical patient is suffering from congestive heart failure with no treatment options and 3 to 6 months to live.  Less than a half liter of blood is extracted from the patient and sent to the company's subsidiary cell processing facility in Israel.  There the patient's stem cells are extracted and grown from tens of thousands into many millions.  The stem cells are primed for angiogenesis or blood vessel formation.  The patient then travels to a jurisdiction where autologous therapy is permitted and has the stem cells transplanted in a hospital in a catheterization laboratory in a procedure similar to angioplasty.

Forward-Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward- looking statements.  These risk factors include, without limitation (i) our ability to obtain additional financing; (ii) our ability to control our expenses; (iii) our ability through our wholly owned foreign subsidiaries to manufacture and market our stem cell treatments; (iv) our ability to initiate and timely complete clinical trials; (v) the timing of and our ability to obtain and maintain regulatory approvals for our stem cell treatments; (vi) our dependence on the success of our lead stem cell treatment; (vii) our inability to predict the extent of our future losses or if or when we will become profitable; (viii) our ability to protect our intellectual property rights; and, (ix) intense competition.  The Company is also subject to the risks and uncertainties described in our filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010 and its Quarterly Report on 'From 10-Q for the quarter ended March 31, 2011.

Contact:

RegenoCELL Therapeutics, Inc.
James F. Mongiardo, Chief Executive Officer
+1-508-647-4065, jmongiardo@regenocell.com


'/>"/>
SOURCE RegenoCELL Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More
2. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
3. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
4. New Research Gives Insight to the Frequency of Doctor Shopping Occurring Within Prescription Monitoring Programs
5. NASDAQ Gives Dynatronics a Second Six-Month Extension for Minimum Bid Price Compliance
6. Frost & Sullivan Market Study Gives Thumbs Up for Pepex™ Trio™ One-Click™ Blood Glucose Meter
7. Serious Eye Disease Gives Birth to Invention of Major New Eye Care Device
8. CareFusion Launches Innovative Vertebral Balloon That Gives Surgeons More Options to Treat Spinal Fractures
9. Web Pharmacy Rxbuys.com Gives Its Customers a 5% Discount Coupon
10. Bureau of Prescription Health Gives the Whole Truth (and Nothing But) About Free Medicine at FreeMedicine.com
11. Spherix Reports Second Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. ... (NASDAQ: IMMY ) ("Imprimis"), an ophthalmology-focused ... Lens ("Precision Lens"), today announced the signing of ... agreement, Precision Lens will deploy a dedicated sales ... geographies in the U.S., primarily focused in 13 ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading provider ... care management module. Using this new feature, sleep physicians can now predict the ... continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea therapy. ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point ... strategies to reduce waste, and support renewable energy. They believe this is a crucial ... to find solutions for health issues, and maintain that destroying the environment in the ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... The ... the glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) ... paparazzi and anyone snapping pictures: the smile. Grins now run the gamut from being ...
Breaking Medicine News(10 mins):